Past, Present, and Future Prospects for Inducing Donor-Specific Transplantation Tolerance for Composite Tissue Allotransplantation

ABSTRACT

Composite tissue allotransplantation (CTA) is among the most immunologically complex and newest transplant fields. Although the field has made considerable advances, there are still concerns that these procedures are performed to enhance quality-of-life issues and are not lifesaving procedures that restore physiologic function. Two challenges limit the widespread application of CTA; the first is chronic rejection, the most prevailing cause of organ allograft failure after transplantation; the second barrier is the numerous health complications associated with lifelong immunosuppressive therapy. Several tolerance-inducing strategies, including costimulatory blockade, T-cell depletion, mixed chimerism, and gene targeting of transplanted organs, have the potential to induce lifelong tolerance to organ allografts without chronic immunosuppression. Effective clinical tolerance protocols that improve CTA acceptance and offer an alternative to the requirement for chronic immunosuppressive therapy could be a major advance in the field. Tolerance would allow allotransplantation to provide a currently unmet need for reconstruction of large tissue defects. This article reviews the history of CTA, current challenges and complications, and offers future directions for CTA research in strategies to induce tolerance.

Composite tissue allotransplantation (CTA) - immunosuppression - tolerance - induction immunosuppression - maintenance immunosuppression

REFERENCES

• 1 Kann B R, Furnas D W, Hewitt C W. Past, present, and future research in the field of composite tissue allotransplantation.  Microsurgery. 2000;  20 393-399
• 2 Kahan B D. Cosmas and Damien revisited.  Transplant Proc. 1983;  15 2211-2216
• 3 Kvernmo H D, Gorantla V S, Gonzalez R N, Breidenbach III W C. Hand transplantation. A future clinical option?.  Acta Orthop. 2005;  76 14-27
• 4 Gilbert R. Transplant is successful with a cadaver forearm.  Med Trib Med Nervs. 1964;  5 20
• 5 DeMartino C. Passing through the threshhold of limb transplantation.  In Motion. 2001;  11 1-4
• 6 Lanzetta M, Petruzzo P, Margreiter R et al.. The International Registry on Hand and Composite Tissue Transplantation.  Transplantation. 2005;  79 1210-1214
• 7 Guimberteau J C, Baudet J, Panconi B, Boileau R, Potaux L. Human allotransplant of a digital flexion system vascularized on the ulnar pedicle: a preliminary report and 1-year follow-up of two cases.  Plast Reconstr Surg. 1992;  89 1135-1147
• 8 Petit F, Minns A B, Dubernard J M, Hettiaratchy S, Lee W P. Composite tissue allotransplantation and reconstructive surgery: first clinical applications.  Ann Surg. 2003;  237 19-25
• 9 Berger A, Lassner F. Peripheral nerve allografts: survey of present state in an experimental model of the rat.  Microsurgery. 1994;  15 773-777
• 10 Mackinnon S E, Doolabh V B, Novak C B, Trulock E P. Clinical outcome following nerve allograft transplantation.  Plast Reconstr Surg. 2001;  107 1419-1429
• 11 Hofmann G O, Kirschner M H, Wagner F D, Land W, Buhren V. Allogeneic vascularized grafting of a human knee joint with postoperative immunosuppression.  Arch Orthop Trauma Surg. 1997;  116 125-128
• 12 Chiron P, Colombier J A, Tricoire J L et al.. A large vascularized allograft of the femoral diaphysis in man.  Int Orthop. 1990;  14 269-272
• 13 Hofmann G O, Kirschner M H, Wagner F D, Brauns L, Gonschorek O, Buhren V. Allogeneic vascularized transplantation of human femoral diaphyses and total knee joints-first clinical experiences.  Transplant Proc. 1998;  30 2754-2761
• 14 Kirschner M H, Brauns L, Gonschorek O, Buhren V, Hofmann G O. Vascularised knee joint transplantation in man: the first two years experience.  Eur J Surg. 2000;  166 320-327
• 15 Strome M. Human laryngeal transplantation: considerations and implications.  Microsurgery. 2000;  20 372-374
• 16 Strome M, Stein J, Esclamado R et al.. Laryngeal transplantation and 40-month follow-up.  N Engl J Med. 2001;  344 1676-1679
• 17 Borel J F, Feurer C, Gubler H U, Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent.  Agents Actions. 1976;  6 468-475
• 18 Matas A J, Payne W D, Sutherland D E et al.. 2,500 living donor kidney transplants: a single-center experience.  Ann Surg. 2001;  234 149-164
• 19 Todo S, Fung J J, Demetris A J, Jain A, Venkataramanan R, Starzl T E. Early trials with FK 506 as primary treatment in liver transplantation.  Transplant Proc. 1990;  22 13-16
• 20 Lubitz S A, Baran D A, Alwarshetty M M et al.. Long-term results of tacrolimus monotherapy in cardiac transplant recipients.  J Heart Lung Transplant. 2006;  25 699-706
• 21 Kobashigawa J A, Miller L W, Russell S D et al.. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report.  Am J Transplant. 2006;  6 1377-1386
• 22 Augustine J J, Chang P C, Knauss T C et al.. Improved renal function after conversion from tacrolimus/sirolimus to tacrolimus/mycophenolate mofetil in kidney transplant recipients.  Transplantation. 2006;  81 1004-1009
• 23 Benhaim P, Anthony J P, Ferreira L, Borsanyi J P, Mathes S J. Use of combination of low-dose cyclosporine and RS-61443 in a rat hindlimb model of composite tissue allotransplantation.  Transplantation. 1996;  61 527-532
• 24 Perez-Abadia G, Laurentin-Perez L, Gorantla V S et al.. Low-dose immunosuppression in a rat hind-limb transplantation model.  Transpl Int. 2003;  16 835-842
• 25 Brinkmann V, Cyster J G, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function.  Am J Transplant. 2004;  4 1019-1025
• 26 Hirose R, Vincenti F. Immunosuppression: today, tomorrow, and withdrawal.  Semin Liver Dis. 2006;  26 201-210
• 27 Birsan T, Dambrin C, Klupp J, Stalder M, Fitzsimmons W E, Morris R E. Effects of the malononitrilamide FK778 on immune functions in vitro in whole blood from non-human primates and healthy human volunteers.  Transpl Immunol. 2003;  11 163-167
• 28 Yamamoto S, Okuda T, Yamasaki K et al.. FK778 controls acute rejection after rat liver allotransplantation showing positive interaction with FK506.  Transplant Proc. 2005;  37 126-129
• 29 Vincenti F. What's in the pipeline? New immunosuppressive drugs in transplantation.  Am J Transplant. 2002;  2 898-903
• 30 Hettiaratchy S, Randolph M A, Petit F, Lee W P, Butler P E. Composite tissue allotransplantation-a new era in plastic surgery?.  Br J Plast Surg. 2004;  57 381-391
• 31 Rowshani A T, Bemelman F J, van Leeuwen E M, van Lier R A. ten B, I. Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients.  Transplantation. 2005;  79 381-386
• 32 Rubin R H, Young L S. Clinical Approach to Infection in the Compromised Host. New York, NY; Plenum Press 1994
• 33 Marty F M, Rubin R H. The prevention of infection post-transplant: the role of prophylaxis, preemptive and empiric therapy.  Transpl Int. 2006;  19 2-11
• 34 First M R, Peddi V R. Malignancies complicating organ transplantation.  Transplant Proc. 1998;  30 2768-2770
• 35 Sheil A G. Organ transplantation and malignancy: inevitable linkage.  Transplant Proc. 2002;  34 2436-2437
• 36 Brenner M J, Tung T H, Jensen J N, Mackinnon S E. The spectrum of complications of immunosuppression: is the time right for hand transplantation?.  J Bone Joint Surg Am. 2002;  84A 1861-1870
• 37 Ojo A O, Held P J, Port F K et al.. Chronic renal failure after transplantation of a nonrenal organ.  N Engl J Med. 2003;  349 931-940
• 38 Gonwa T A, Mai M L, Melton L B et al.. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.  Transplantation. 2001;  72 1934-1939
• 39 Hendawy A, Pouteil-Noble C, Villar E, Boissonnat P, Sebbag L. Chronic renal failure and end-stage renal disease are associated with a high rate of mortality after heart transplantation.  Transplant Proc. 2005;  37 1352-1354
• 40 Lee W P, Yaremchuk M J, Pan Y C, Randolph M A, Tan C M, Weiland A J. Relative antigenicity of components of a vascularized limb allograft.  Plast Reconstr Surg. 1991;  87 401-411
• 41 Duquesnoy R J. Is histocompatibility testing needed for composite tissue transplantation?.  Transplant Proc. 1998;  30 2724-2728
• 42 Trulock E P. Lung and heart-lung transplantation: overview of results.  Semin Respir Crit Care Med. 2001;  22 479-488
• 43 Felker G M, Hernandez A F, Rogers J G et al.. Cardiac transplantation at Duke University Medical Center.  Clin Transpl. 2004;  235-241
• 44 Perez-Simon J A, Sanchez-Abarca I, ez-Campelo M, Caballero D, San M J. Chronic graft-versus-host disease: pathogenesis and clinical management.  Drugs. 2006;  66 1041-1057
• 45 Morelli A E, Thomson A W. Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction.  Immunol Rev. 2003;  196 125-146
• 46 Fugier-Vivier I J, Rezzoug F, Huang Y et al.. Plasmacytoid precursor dendritic cells facilitate allogeneic hematopoietic stem cell engraftment.  J Exp Med. 2005;  201 373-383
• 47 Pei G, Gu L, Yu L. A preliminary report of two cases of human hand allograft.  Zhonghua Yi Xue Za Zhi. 2000;  80 417-421
• 48 Kirk A D, Hale D A, Mannon R B et al.. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).  Transplantation. 2003;  76 120-129
• 49 Levi D M, Tzakis A G, Kato T et al.. Transplantation of the abdominal wall.  Lancet. 2003;  361 2173-2176
• 50 Kaufman D B, Leventhal J R, Gallon L G, Parker M A. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction-long-term results.  Am J Transplant. 2006;  6 331-339
• 51 Axelrod D, Leventhal J R, Gallon L G, Parker M A, Kaufman D B. Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients.  Am J Transplant. 2005;  5 1423-1429
• 52 Pham S M, Jimenez J, Bednar B M et al.. Capath-1H in clinical heart transplantation. Presented at: International Society of Heart and Lung Transplantation April 5-8, 2006 Madrid, Spain; [abstract 236]
• 53 Trombetta E S, Mellman I. Cell biology of antigen processing in vitro and in vivo.  Annu Rev Immunol. 2005;  23 975-1028
• 54 Lutz M B, Suri R M, Niimi M et al.. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo.  Eur J Immunol. 2000;  30 1813-1822
• 55 Taylor K N, Shinde Patil V R, Chittentenden M, Colson Y L. FcRγ-dependent facilitating cells are direct inducers of regulatory T cells. Presented at: 47th ASH Annual Meeting and Exposition December 10-13, 2005 Atlanta, GA; [abstract 65]
• 56 Yoshimura S, Bondeson J, Foxwell B M, Brennan F M, Feldmann M. Effective antigen presentation by dendritic cells is NF-kappaB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines.  Int Immunol. 2001;  13 675-683
• 57 Allen S D, Rawale S V, Whitacre C C, Kaumaya P T. Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade.  J Pept Res. 2005;  65 591-604
• 58 Viola A, Schroeder S, Sakakibara Y, Lanzavecchia A. T lymphocyte costimulation mediated by reorganization of membrane microdomains.  Science. 1999;  283 680-682
• 59 Quezada S A, Jarvinen L Z, Lind E F, Noelle R J. CD40/CD154 interactions at the interface of tolerance and immunity.  Annu Rev Immunol. 2004;  22 307-328
• 60 Elster E A, Xu H, Tadaki D K et al.. Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates.  Transplantation. 2001;  72 1473-1478
• 61 Koyama I, Kawai T, Andrews D et al.. Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates.  Transplantation. 2004;  77 460-462
• 62 Haspot F, Seveno C, Dugast A S et al.. Anti-CD28 antibody-induced kidney allograft tolerance related to tryptophan degradation and TCR class II B7 regulatory cells.  Am J Transplant. 2005;  5 2339-2348
• 63 Siemionow M, Ortak T, Izycki D et al.. Induction of tolerance in composite-tissue allografts.  Transplantation. 2002;  74 1211-1217
• 64 Larsen C P, Elwood E T, Alexander D Z et al.. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways.  Nature. 1996;  381 434-438
• 65 Bagley J, Tian C, Sachs D H, Iacomini J. Induction of T-cell tolerance to an MHC class I alloantigen by gene therapy.  Blood. 2002;  99 4394-4399
• 66 Lowenstein P R. The case for immunosuppression in clinical gene transfer.  Mol Ther. 2005;  12 185-186
• 67 Ildstad S T, Sachs D H. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts.  Nature. 1984;  307 168-170
• 68 Colson Y L, Xu H, Huang Y, Ildstad S T. Mixed xenogeneic chimerism induces donor-specific humoral and cellular immune tolerance for cardiac xenografts.  J Immunol. 2004;  173 5827-5834
• 69 Pham S M, Mitruka S N, Youm W et al.. Mixed hematopoietic chimerism induces donor-specific tolerance for lung allografts in rodents.  Am J Respir Crit Care Med. 1999;  159 199-205
• 70 Li H, Kaufman C L, Ildstad S T. Allogeneic chimerism induces donor-specific tolerance to simultaneous islet allografts in non-obese diabetic (NOD) mice.  Surgery. 1995;  118 192-198
• 71 Li H, Abou El-Ezz A Y, Gambrell B E, Ildstad S T. Mixed xenogeneic chimerism and tolerance III: A nonlethal approach to induce donor-specific transplantation tolerance to simultaneous islet xenografts.  Transplantation. 1995;  60 59-65
• 72 Chien J W, Maris M B, Sandmaier B M, Maloney D G, Storb R F, Clark J G. Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation.  Biol Blood Marrow Transplant. 2005;  11 288-296
• 73 Sayegh M H, Fine N A, Smith J L, Rennke H G, Milford E L, Tilney N L. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors.  Ann Intern Med. 1991;  114 954-955
• 74 Wekerle T, Kurtz J, Ito H et al.. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment.  Nat Med. 2000;  6 464-469
• 75 Prabhune K A, Gorantla V S, Perez-Abadia G et al.. Composite tissue allotransplantation in chimeric hosts part II. A clinically relevant protocol to induce tolerance in a rat model.  Transplantation. 2003;  76 1548-1555
• 76 Demir Y, Ozmen S, Klimczak A, Mukherjee A L, Siemionow M. Tolerance induction in composite facial allograft transplantation in the rat model.  Plast Reconstr Surg. 2004;  114 1790-1801
• 77 Foster R D, Pham S, Li S, Aitouche A. Long-term acceptance of composite tissue allografts through mixed chimerism and CD28 blockade.  Transplantation. 2003;  76 988-994
• 78 Li S, Thanikachalam M, Pang M, Carreno M, Aitouche A, Pham S M. Combined host-conditioning with CTLA4-Ig, tacrolimus, anti-lymphocyte serum, and low-dose radiation leads to stable mixed hematopoietic chimerism.  Exp Hematol. 2001;  29 534-541
• 79 Isik S, Er E, Soysal Y, Imrzalioglu N. Prolongation of skin xenograft survival with modified cultured fibroblasts.  Plast Reconstr Surg. 2003;  111 275-282
• 80 Siemionow M, Demir Y, Mukherjee A, Klimczak A. Development and maintenance of donor-specific chimerism in semi-allogenic and fully major histocompatibility complex mismatched facial allograft transplants.  Transplantation. 2005;  79 558-567
• 81 Siemionow M, Zielinski M, Ozmen S, Izycki D. Intraosseus transplantation of donor-derived hematopoietic stem and progenitor cells induces donor-specific chimerism and extends composite tissue allograft survival.  Transplant Proc. 2005;  37 2303-2308